Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Exploring the curative potential of BCR-ABL1-targeting drugs for chronic myeloid leukaemia.

Valent P.

Lancet Oncol. 2010 Nov;11(11):1010-1. doi: 10.1016/S1470-2045(10)70243-6. Epub 2010 Oct 19. No abstract available.

PMID:
20965784
2.

Patient with chronic myeloid leukemia in complete cytogenetic response: what does it mean, and what does one do next?

Marin D.

J Clin Oncol. 2014 Feb 10;32(5):379-84. doi: 10.1200/JCO.2013.52.9230. Epub 2014 Jan 13. Review. No abstract available.

PMID:
24419129
3.

Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.

Martinelli G, Iacobucci I, Soverini S, Cilloni D, Saglio G, Pane F, Baccarani M.

Hematol Oncol. 2006 Dec;24(4):196-204. Review.

PMID:
16988930
4.

[Trends in molecular targeting therapeutics for chronic myeloid leukemia].

Nagai T.

Rinsho Ketsueki. 2007 Oct;48(10):1360-9. Review. Japanese. No abstract available.

PMID:
17933121
5.

The significance of early, major and stable molecular responses in chronic myeloid leukemia in the imatinib era.

Breccia M, Alimena G.

Crit Rev Oncol Hematol. 2011 Aug;79(2):135-43. doi: 10.1016/j.critrevonc.2010.07.003. Epub 2010 Aug 4. Review.

PMID:
20685131
6.

Switching off oncogenic signals in chronic myeloid leukaemia.

Melo J, Barnes DJ.

Hematol J. 2004;5 Suppl 3:S183-7. Review. No abstract available.

PMID:
15190305
7.

[Chronic myeloid leukemia: up-to-date management].

Nakayama K, Inokuchi K.

Rinsho Ketsueki. 2014 Jan;55(1):42-55. Review. Japanese. No abstract available.

PMID:
24492036
8.

[Treatment of chronic myeloid leukemia in chronic phase].

Matsumura I.

Rinsho Ketsueki. 2014 Oct;55(10):1853-9. Review. Japanese. No abstract available.

PMID:
25297749
9.

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.

Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD.

Nat Rev Cancer. 2007 May;7(5):345-56. Review.

PMID:
17457302
10.

Monitoring treatment of chronic myeloid leukemia.

Baccarani M, Pane F, Saglio G.

Haematologica. 2008 Feb;93(2):161-9. doi: 10.3324/haematol.12588. Review. No abstract available.

11.

New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.

O'Hare T, Eide CA, Deininger MW.

Expert Opin Investig Drugs. 2008 Jun;17(6):865-78. doi: 10.1517/13543784.17.6.865 . Review.

PMID:
18491988
12.

Monitoring BCR-ABL in the treatment of chronic myeloid leukemia by polymerase chain reaction.

Oehler VG, Radich JP.

Curr Hematol Malig Rep. 2006 Sep;1(3):152-9. doi: 10.1007/s11899-996-0003-x. Review.

PMID:
20425346
13.

[Mechanisms of resistance to BCR-ABL kinase inhibitors].

Diamond J, da Silva MG.

Acta Med Port. 2013 Jul-Aug;26(4):402-8. Epub 2013 Aug 30. Review. Portuguese.

14.

New strategies in controlling drug resistance in chronic myeloid leukemia.

Frame D.

Am J Health Syst Pharm. 2007 Dec 15;64(24 Suppl 15):S16-21. Review.

PMID:
18056927
15.

Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.

Jabbour E, Cortes J, Kantarjian H.

Expert Opin Investig Drugs. 2007 May;16(5):679-87. Review. Erratum in: Expert Opin Investig Drugs. 2007 Jul;16(7):1135.

PMID:
17461740
16.

[Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].

Usui N.

Rinsho Byori. 2004 Feb;52(2):136-44. Review. Japanese.

PMID:
15027317
17.

The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib.

Deadman BJ, Hopkin MD, Baxendale IR, Ley SV.

Org Biomol Chem. 2013 Mar 21;11(11):1766-800. doi: 10.1039/c2ob27003j. Epub 2012 Dec 18. Review.

PMID:
23247657
18.

Glivec and CML: a lucky date.

Saglio G, Cilloni D, Rancati F, Boano L.

J Biol Regul Homeost Agents. 2004 Apr-Jun;18(2):246-51. Review.

PMID:
15739279
19.

[Therapeutic drug management of BCR-ABL tyrosine kinase inhibitor for chronic myeloid leukemia patients].

Miura M, Takahashi N.

Rinsho Ketsueki. 2013 Oct;54(10):1720-9. Review. Japanese. No abstract available.

PMID:
24064822
20.

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when is this a safe option to consider?

Sweet K, Oehler V.

Hematology Am Soc Hematol Educ Program. 2013;2013:184-8. doi: 10.1182/asheducation-2013.1.184. Review.

PMID:
24319180

Supplemental Content

Support Center